Occam Places Mark Strobeck on the Board of Windtree
_440x352.avif)
Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders has appointed Mark Strobeck, Ph.D. to its Board of Directors.
Mark comes to Windtree with more than 20 years of richly varied experience in operations, business development, capital raising, and M&A. Currently, he serves as President and CEO, and Board Member of Rockwell Medical, a publicly held healthcare company that develops, manufactures, commercializes, and distributes a portfolio of products for dialysis providers worldwide.
Prior to joining Rockwell in 2022, Mark was a Managing Partner at Aquilo Partners, a life science investment banking firm specializing in M&A and strategic partnering transactions. Previous executive roles have found him at Zyla Lifesciences (acquired by Assertio Therapeutics), Corridor Pharmaceuticals (acquired by AstraZeneca), Topaz Pharmaceuticals (acquired by Sanofi Pasteur), and GSK.
Mark holds a Ph.D. in pharmacology and cell biophysics from the University of Cincinnati.
Recent Placements
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.